Immune Therapies in Multiple Myeloma

摘要: Treatment paradigms have changed rapidly for multiple myeloma, and immune therapies taken center stage. Advances in myeloma led to a dramatic improvement the survival of patients with this incurable malignancy. The system is significantly impaired as result disease leading suppression normal plasma cells well negative effects on cellular immunity. Given scenario, approaches not been successful until recently. Monoclonal antibodies directed against CD38 (daratumumab) SLAMF7 (elotuzumab) are already clinic, several other different cell antigens under evaluation. Although checkpoint inhibition PD-1 inhibitors had no clinical efficacy when were used single agents, it has some results combined immunomodulatory drugs such lenalidomide pomalidomide. Vaccination strategies shown vivo responses but clear efficacy. Newer vaccination antigens, combinations setting minimal residual disease, all increased possibility approach succeeding. Ex effector expansion also appears be promising trials. Finally, chimeric antigen receptor T-cell promise based isolated reports success remains an area intense investigation. Immune-based can potentially augment or even supplant current and, given low toxicity profile, may hold great potential early treatment precursor-stage diseases. Clin Cancer Res; 22(22); 5453-60. ©2016 AACR SEE ALL ARTICLES IN THIS CCR FOCUS SECTION, "MULTIPLE MYELOMA MULTIPLYING THERAPIES".